Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryce P Portier

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
New Biotechnology|April 17, 2012
From morphologic to molecular: established and emerging molecular diagnostics for breast carcinomaBryce P Portier, Aaron M Gruver, Michael A Huba, et al.
Oncotarget|October 5, 2013
HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinomaBryce P Portier, Eugen C Minca, Zhen Wang, et al.
Cancer|February 14, 2017
Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancerAlana R Donaldson, Shashirekha Shetty, Zhen Wang, et al.
Archives of Pathology & Laboratory Medicine|January 28, 2022
Neoplastic Cellularity Assessment in Molecular TestingKelly A Devereaux, Rhona J Souers, Rondell P Graham, et al.
Molecular Cancer Therapeutics|July 24, 2014
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITDWarren Fiskus, Sunil Sharma, Jun Qi, et al.
American Journal of Clinical Pathology|October 15, 2013
Ultrasensitive RNA in situ hybridization for detection of restricted clonal expression of low-abundance immunoglobulin light chain mRNA in B-cell lymphoproliferative disordersRaymond R Tubbs, Hongwei Wang, Zhen Wang, et al.
The Journal of Molecular Diagnostics : JMD|March 19, 2013
ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISHEugen C Minca, Bryce P Portier, Zhen Wang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 18, 2012
Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistryBryce P Portier, Zhen Wang, Erinn Downs-Kelly, et al.
The Journal of Molecular Diagnostics : JMD|January 12, 2013
Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinomaZhen Wang, Bryce P Portier, Aaron M Gruver, et al.
American Journal of Clinical Pathology|March 13, 2014
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencingBryce P Portier, Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
New Biotechnology|April 17, 2012
From morphologic to molecular: established and emerging molecular diagnostics for breast carcinomaBryce P Portier, Aaron M Gruver, Michael A Huba, et al.
Oncotarget|October 5, 2013
HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinomaBryce P Portier, Eugen C Minca, Zhen Wang, et al.
Cancer|February 14, 2017
Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancerAlana R Donaldson, Shashirekha Shetty, Zhen Wang, et al.
Archives of Pathology & Laboratory Medicine|January 28, 2022
Neoplastic Cellularity Assessment in Molecular TestingKelly A Devereaux, Rhona J Souers, Rondell P Graham, et al.
Molecular Cancer Therapeutics|July 24, 2014
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITDWarren Fiskus, Sunil Sharma, Jun Qi, et al.
American Journal of Clinical Pathology|October 15, 2013
Ultrasensitive RNA in situ hybridization for detection of restricted clonal expression of low-abundance immunoglobulin light chain mRNA in B-cell lymphoproliferative disordersRaymond R Tubbs, Hongwei Wang, Zhen Wang, et al.
The Journal of Molecular Diagnostics : JMD|March 19, 2013
ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISHEugen C Minca, Bryce P Portier, Zhen Wang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 18, 2012
Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistryBryce P Portier, Zhen Wang, Erinn Downs-Kelly, et al.
The Journal of Molecular Diagnostics : JMD|January 12, 2013
Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinomaZhen Wang, Bryce P Portier, Aaron M Gruver, et al.
American Journal of Clinical Pathology|March 13, 2014
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencingBryce P Portier, Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, et al.
Pageof 3